Multiple Myeloma Clinical Trials in Atlanta

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
J
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Not yet recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +95 more
2021-10-08
Oct 8, 2021
P
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Recruiting
  • Multiple Myeloma
  • Elranatamab (PF-06863135)
  • Beverly Hills, California
  • +85 more
2021-10-14
Oct 14, 2021
R
First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Miami, Florida
  • +14 more
2021-10-07
Oct 7, 2021
J
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +79 more
2021-10-14
Oct 14, 2021
J
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Daratumumab IV
  • +3 more
  • Birmingham, Alabama
  • +211 more
2021-10-14
Oct 14, 2021
J
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +100 more
2021-10-14
Oct 14, 2021
S
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Recruiting
  • Multiple Myeloma
  • Anchorage, Alaska
  • +533 more
2021-10-08
Oct 8, 2021
M
An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6)
Active, not recruiting
  • Multiple Myeloma
  • Tucson, Arizona
  • +32 more
2021-10-08
Oct 8, 2021
C
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product - 2021
Terminated
  • B Cell Lymphomas
  • +3 more
  • ACTR T Cell Product
  • Gilbert, Arizona
  • +15 more
2021-10-04
Oct 4, 2021
J
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • San Francisco, California
  • +41 more
2021-10-07
Oct 7, 2021
J
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Birmingham, Alabama
  • +35 more
2021-10-07
Oct 7, 2021
J
A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • Daratumumab Subcutaneous (SC) Administration
  • Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
  • Atlanta, Georgia
  • +11 more
2021-10-07
Oct 7, 2021
J
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • Little Rock, Arkansas
  • +56 more
2021-10-07
Oct 7, 2021
J
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +27 more
2021-10-07
Oct 7, 2021
J
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • Duarte, California
  • +21 more
2021-10-07
Oct 7, 2021
P
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Active, not recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +45 more
2021-10-06
Oct 6, 2021
C
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +25 more
2021-10-05
Oct 5, 2021
J
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Little Rock, Arkansas
  • +145 more
2021-09-16
Sep 16, 2021
G
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • San Francisco, California
  • +5 more
2021-10-01
Oct 1, 2021
A
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Eftozanermin alfa
  • +2 more
  • Atlanta, Georgia
  • +18 more
2021-10-04
Oct 4, 2021
G
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Belantamab mafodotin frozen liquid
  • Belantamab mafodotin lyophilized powder
  • New Haven, Connecticut
  • +58 more
2021-09-30
Sep 30, 2021
G
Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)
Active, not recruiting
  • Multiple Myeloma
  • Atlanta, Georgia
  • +11 more
2021-09-30
Sep 30, 2021
N
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Recruiting
  • Multiple Myeloma
  • +2 more
  • Goodyear, Arizona
  • +13 more
2021-09-30
Sep 30, 2021
K
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Plantation, Florida
  • +156 more
2021-09-24
Sep 24, 2021
S
PRospective Multiple Myeloma Impact Study
Active, not recruiting
  • Multiple Myeloma
  • MMprofiler SKY92 gene signature
  • Washington, District of Columbia
  • +8 more
2021-09-23
Sep 23, 2021